This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Yet, the healthcare experience often begins with a decidedly analog ritual: The dreaded patient intake form. While medicalscience advances, too many clinics still rely on cumbersome paperwork. Its simple: Digital patient intake forms. What is Digital Patient Intake? Whats the solution to such an age-old problem?
Traditionally, Medical Affairs has focused on cross-functional collaboration with commercial and R&D teams, medical communication, evidence generation, and dissemination. MSLs are key purveyors of scientific truth and viewed highly by HCPs/KOLs, and they are driven by their passion to help patients.
In the healthcare Operations field, achieving the best possible patient outcomes is paramount. This means ensuring patients not only understand their diagnosis but are also empowered to participate actively in their treatment plan. It utilizes computer-generated simulations to create realistic and interactive environments.
Personalized Medicine Thanks to AI, we will create simulations of the human body at the molecular, cellular and organ levels, allowing treatments to be personalized for each patient. This will lead to treatments that are more effective and safer, as the specificities of each patient will be taken into account.
However, the Autumn Budget provides some relief via additional funding for the strained NHS, a welcome outcome considering for example, that “record numbers of cancer patients are having to wait longer than they should to begin their treatment”, explained Naser Turabi, Director of Evidence and Implementation at Cancer Research UK.
In recent years, there has been an increased focus on real world evidence to advance medicalscience and improve patient quality of life. Data lags can extend the duration of diagnostic studies substantially, ultimately delaying patient access to life-saving medications.
It has been designed to address the unmet needs of patients and to provide quick action and well-tolerated dry eye drug therapy. Novaliq medicalscience and regulatory affairs vice-president Sonja Krösser stated: “We are proud that the FDA approved VEVYE.
In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). Rarely are organisations able to view HCP relationships holistically – across clinical, medical, and sales – or reap the benefits of creating a unified understanding of the customer.
Medical communications must be able to offer useful information to HCPs when questions arise, whether that’s in the clinic with a patient or in a surgical theatre.
These are dynamic factors, playing out differently across specialty groups and stages of the patient journey, as well as the condition being treated. Clarivate’s Taking the Pulse series of global physician studies is designed to help companies better support their physician customers in caring for patients. In contrast, half of U.S.
“NEJM is pleased to participate in an innovative new service from CCC that aligns with our goal to meet the information needs of researchers for the highest quality studies in medicalscience,” said Rob McKinney, Director, NEJM Group Licensing. NEJM is recognized as the world’s leading medical journal and website.
With the development of new technology platforms at breakneck speed, companies are positioning themselves to one day deliver game-changing solutions to patients in their niche—solutions they may have been waiting for all their life. At what point in the patient journey are you most likely to discover the answers you were looking for?
These, in turn, result in stronger accountability and more trust with those who matter most: HCPs and patients. MSL Training Becomes More Strategic MedicalScience Liaisons (MSLs) play a critical role in bridging scientific data with clinical practice.
In this era of grab-and-go learning, continuing medical education (CME) is being transformed by digital and AI technology, which tailors learning to meet individual HCP needs. This approach enhances patient outcomes and care by delivering education at the most receptive moments for healthcare professionals.
As medical treatments become more complex, the role of the MedicalScience Liaison (MSL) has never been more important. Louise Picken , EVP Head of Medical Services, Complete HealthVizion. She brings over 20 years of experience in medical communications and medical training.
Mobilize MSLs Peer-to-Peer demand is driving reliance on social media to connect HCPs with others serving similar patient populations or confronting similar treatment considerations. Doctors love to talk to each other, especially when they share questions and concerns.
The primary purpose of MedicalScience Liaison MSL is to establish and maintain peer-peer relationships with leading physicians, referred to as Key Opinion Leaders KOL’s, at major academic institutions and clinics. Asking strategic questions leads to a better understanding of medical practices and habits.
Following their introduction, these therapies have moved to early lines of treatment, but unfortunately, a significant number of patients are not cured with these approaches. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.
Kaitlin Anstett , Senior Medical Advisor at Theratechnologies , will sit down with Natalie Yeadon , Co-founder & CEO of Impetus Digital , to share her unique insights into the way Medical Affairs teams are changing the way they are engaging and interacting with their most important stakeholders in the “new normal.” Sign up now!
Measuring medical affairs is key to driving clinical innovation, engaging scientific communities, and improving patient outcomes. To justify investment in medical affairs, it’s important to demonstrate impact and align stakeholders with different priorities. Measuring medical affairs success is challenging. References: 1.[link]
Although effective, the inconvenience of regular injections can lead to poor patient adherence, with studies showing that persistence and adherence are generally better for oral medications compared with injections. We can see a future where millions of patients no longer carry the burden of regular injections.”
Medicalscience Liaisons know that change is coming; How are they cashing in? Medicalscience liaisons (MSLs) within pharmaceutical companies deal in a special currency: scientific exchange and real-world insights gathering.
The main source of new and up-to-date information on medical research, clinical trials, treatment recommendations, and developments in medicalscience is medical journals. Making wise medical decisions and giving patients the best treatment possible depend on this.
The first human trial done in Israel proved very successful (2017-2018, finalized during COVID), and published in the Red Journal , the official journal of the American Society for Radiation Oncology), involving many patients whose cancer recurred after treatment or whose options were exhausted. The rest of the patients had partial responses.
When the first biosimilars were approved by the FDA almost a decade ago, they were expected to provide a cost-effective alternative to expensive biologics, improve accessibility for patients and reduce healthcare spending by creating competition in the biologic market. Overall, the findings of the analysis were positive.
All of these systems operate under the “master-slave” concept, which involves a surgeon sitting behind a console, away from the patient, who manipulates the mechanical arms of the robot via some kind of joystick-like device. More info can be found at the Biomed Israel website.
Field Medical Affairs is an essential bridge between pharmaceutical clinical development and commercial delivery. Historically, the industry has left MSL-HCP interactions to exist on their own, focusing on objective metrics and key performance indicators (KPIs) to inform Medical Affairs impact.
Neuromodulation isn’t just about stimulating nerves; it’s about awakening hope and transforming lives—one patient at a time. In this episode, Blake Williams takes us on a wild journey through his career as a Field Clinical Engineer (FCE), shedding light on the incredible impact of neuromodulation on the lives of patients.
This engagement is continuing to remain high, with evolving requirements and preferences of healthcare practitioners (HCPs) in the ways they engage with pharma reps and medicalscience liaisons (MSLs) through virtual communications. Five steps to closing the CX gap with HCPs and Patients. Get stakeholder buy in on the “why”.
The time-consuming and resource-intensive path from the lab bench to the patient bedside starts with drug discovery, progresses to pre-clinical and clinical research, and then enters regulatory review. Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most.
AI is also making waves in how to find and target patient communities as healthcare privacy legislation continues to expand in the United States. Dstillery, a custom audience solution, predicts impression opportunities through AI modeling that identifies patient patterns without using any cookie-based identification.
Healthcare providers (HCPs), payers, and patients can now access medical information at their fingertips and they expect more from Pharma than in the past. This increased focus on patients and diverse stakeholders will undoubtedly be facilitated by the accelerated uptake of digital tools and virtual collaboration solutions.
contact information, medical specialties, accepted insurances, business hours, location, patient testimonials, and more) directly on the SERP. MedicalSpecialty Any specific branch of medicalscience or practice, including clinical specialties about organ systems and their respective diseases and allied health specialties.
Heavy patient loads, paperwork, research, presentations at medical meetings, and department/academic obligations make it tough to keep up with the literature, new therapies, and understanding of how community level and peers manage their patients. More than ever, physician time is at a premium.
MedicalScience Liaisons are hired or contracted to meet with these stakeholders prior to and during the launch and distribution period to educate and create awareness of the drug. Secondary: These are those who will ultimately determine the lifecycle and success of advanced treatments, diagnostic tools, and medications.
With this comes new hope for previously underserved patient populations. Acting as a go-between for pharma and physicians, medicalscience liaisons (MSLs) are responsible for communicating necessary information about new medicines to healthcare professionals and key opinion leaders (KOLs). Expanding horizons.
This means that during the Q&A session, you may face a myriad of intricate medical, functional, or operational questions. A MedicalScience Liaison’s job is to build relationships, so distinguishing yourself in these ways is paramount. For a MedicalScience Liaison, having medical knowledge is a given necessity.
Well, yes, when patients got the migraine products that I sold, I knew for a fact that it would change their lives, but I didn’t get to see that directly. So you’re saying that, as a recruiter in that kind of space, it’s one thing to be helping people that are that removed from the patient impact. That is amazing.
Some companies using virtual technology have already reduced clinical trial times by 40% and reduced the number of patients required for testing by two thirds, says Arlington. “It’s very disappointing.
They have to meet with doctors, nurses, and healthcare administrators to whom they will have to present products, conduct demonstrations, and discuss patient needs and how offering meets them. The magnitude of the rewards far outweighs them. Product Manager: Manage specific product portfolio including positioning, pricing, and messaging.
The early-stage venture financing firm Canaan Partners focuses on game-changing innovations in information, digital technologies, and the medicalsciences. Over the last 31 years, the firm has managed a highly diversified $5 billion fund that comprises some of the top names in technology and life sciences. Canaan Partners.
Here is one of the entry-level resume examples you can use: Education: Bachelor of Science in Basic MedicalSciences (GPA: 3.8) Shine a light on your academic achievements, such as honors, scholarships, or research projects, to underscore your commitment to excellence in your field.
As treatments become more tailored to individual patients, sales reps must understand complex scientific concepts and communicate them effectively. You need to comprehend and convey how these products can truly make a difference in patients' lives. Another game-changer has been the shift towards personalized medicine.
3 With greater scientific understanding of cancer, the industry has made significant progress in developing innovative medicines to help patients. However, access to these medicines is not close to meeting patient demand, creating inequalities in the health prospects of those diagnosed with cancer. 1,2 In the EU, an estimated 2.7
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content